Antifungal drugs have been proposed as a novel treatment for Acanthamoeba keratitis. The cysticidal activity of several antifungal compounds was tested against different genotypes of culture collection and clinical isolates of Acanthamoeba. Only voriconazole and posaconazole were found to be cysticidal, with no differences in activity observed between clinical and culture collection isolates.
weeks to obtain complete encystment. PYG flasks were then placed on ice for 10 s and gently shaken to dislodge the cysts from the flask walls, and 0.100-l aliquots of PYG containing 10 5 cysts per ml were then prepared by manual counting with a hemocytometer.
The Sensititre Yeastone plate (TREK Diagnostic Systems, Cleveland, OH) is a microtiter broth dilution plate for antifungal sensitivity testing (17, 18) . The plate contains seven dried antifungal drugs at 2-fold dilutions (Table 2) . Serial dilutions of voriconazole and posaconazole (1, 5, 10, 20, 40, 80, 160 , and 320 g/ml) were prepared separately.
Cyst aliquots in PYG were incubated with antifungal drugs at 35°C for 48 h. Subsequently, the aliquots were plated on nonnutrient agar (NNA) plates layered with Escherichia coli, incubated at 35°C, and observed with an inverted microscope daily for 1 week to detect growth. Growth was defined as the presence of excysted trophozoites found growing on the culture plates. At the 3-day time point, a fresh inoculum of Escherichia coli (Pro-Lab Diagnostics, Round Rock, TX) (about 900 ϫ 10 6 CFU/ml; McFarland turbidity standard) was applied on the plates to ensure a The MCCs for voriconazole were 33.13 Ϯ 22.83 g/ml for clinical isolates and 46.25 Ϯ 23.26 g/ml for culture collection strains (the mode value for both groups was 40 g/ml). The MCCs for posaconazole were 43.75 Ϯ 25.04 g/ml for clinical isolates and 52.5 Ϯ 23.75 g/ml for culture collection strains (the mode value for both groups was 40 g/ml) ( Fig. 1 and Table 3 ). No significant differences between clinical and culture collection isolates in the average cysticidal concentrations for voriconazole and posaconazole were found (P Ͼ 0.05) (Fig. 1) .
Our study showed that newer triazoles such as voriconazole and posaconazole do possess cysticidal activity and could represent a potential therapeutic agent for treatment of AK. These drugs inhibit the synthesis of ergosterol, which is a major component of the Acanthamoeba cell membrane. Our results are in line with what previously reported by other authors in previous studies (6, 8, 9) . In the studies by Cabello-Vilchez and Martín-Navarro, the voriconazole 90% inhibitory concentration (IC) for cysts was shown to be around 5 to 15 g/ml for the tested isolates. The higher inhibitory concentration found in our study might be a consequence of the different methodology and the higher number of isolates tested. The cysticidal activity of posaconazole against Acanthamoeba had never previously been tested.
None of the other antifungal drugs tested in the Sensititre Yeastone microdilution plate showed any cysticidal activity. A cysticidal effect could have been evident only at concentrations much higher than the ones resulting in activity against filamentary fungi or yeasts. Among all the antifungal drugs, only caspofungin was previously identified as a potential antiamoebic agent and tested against cysts in vitro. Echinocandins impair the synthesis of ␤-glucan, which is expressed at high levels during encystment. In a previous study, caspofungin was cysticidal only at a concentration of 500 g/ml (7).
In conclusion, our in vitro findings support the potential use of newer triazoles as antiamoebic agents. Further in vivo studies would be needed to confirm the potential role of these compounds in the treatment of AK. 
